 Ionis Pharmaceuticals Inc NASDAQ: IONS said it expanded its distribution agreement with Swedish Orphan Biovitrum AB Sobi for Tegsedi in North America. Tegsedi is indicated for polyneuropathy a condition where multiple peripheral nerves become damaged in adults with hereditary transthyretin amyloidosis. 